Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-05180999 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-05180999 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-05180999 | DRUG | Ascending single oral doses of 0.1, 0.3, 1.0, 3, 10, 30, 100, and 250 mg oral solution or capsules |
| Placebo | DRUG | Placebo oral solution or capsules |
Inclusion Criteria: male or female of non-childbearing potential, Exclusion Criteria: Evidence of clinically significant medical illness, history of seizures, any condition possibly affecting drug absorption
Top 15 of 16 competitors
PF-05180999 is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE) for schizophrenia. It is in Phase 1 clinical development and has been studied in a single completed trial. It is not approved for any indication.
PF-05180999 is being evaluated as a potential treatment for schizophrenia. The only clinical trial to date was a Phase 1 study in healthy adult volunteers, not in patients with schizophrenia. No efficacy in schizophrenia has been established.
PF-05180999 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 trial of the compound.
PF-05180999 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any other regulatory agency. The single Phase 1 trial has been completed.
PF-05180999 has been studied in one completed Phase 1 trial, NCT01429740, titled A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults. It enrolled 29 healthy adult participants in the United States and was randomized, double-blind, and placebo-controlled.